Key Takeaways

Researchers reviewed 48 trials with more than 94,000 adults taking GLP-1 drugs

Results found little to no effect on the risk of 13 obesity-related cancers

Experts say longer-term studies are still needed

WEDNESDAY, Dec. 10, 2025 (HealthDay News) — A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound , may not lower cancer risk as some had hoped.

Researchers analyzed 48 randomized trials including 94,245 adults who were overweight, obese or had type 2 diabetes. More than 51,000 people took a GLP-1 drug, and nearly 43,000 received a placebo and were followed for about 70 weeks.

The team wanted to know whether these medications change someone’s risk of developing any of the 13 cancers linked to obesity. The results showed GLP-1 drugs had little to no eff

See Full Page